Skip to main content
Skip to section navigation
Skip to footer
Home
About Us
Our Leadership
Our Science
Introduction to
FcRn
Pipeline & Therapeutic Areas
Patients & Caregivers
Our Commitment
Therapeutic Areas & Clinical Trials
For Investors
Overview
News & Events
Company Info
Financials
Stock Data
SEC Filings
Governance
Join Us
Values & Culture
Explore Careers
Contact Us
Presentations
View Main Content
For Investors
For Investors
Overview
News & Events
Overview
Press Releases
IR Calendar
Presentations
Email Alerts
Company Info
Overview
Executive Leadership Team
Contacts
FAQ
Financials
Overview
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
Overview
All SEC Filings
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Whistleblower Policy
December 15, 2024
Corporate Presentation
November 7, 2024
Immunovant Development Update
September 9, 2024
Immunovant Graves’ Disease Program Update
January 9, 2024
42nd Annual J.P. Morgan Healthcare Conference Presentation
November 28, 2023
Immunovant Portfolio Update
September 26, 2023
IMVT-1402 Initial Phase 1 Results
June 8, 2022
Investor Presentation June 8, 2022
January 10, 2022
Phase 3 Development for Batoclimab in Myasthenia Gravis
rss_feed
RSS
Email Alerts
Contacts
RSS News Feed
